Evaluation of novel 2-(quinoline-2-ylthio)acetamide derivatives linked to diphenyl-imidazole as α-glucosidase inhibitors: Insights from in silico , in vitro , and in vivo studies on their anti-diabetic properties
Minoo Khalili Ghomi,Milad Noori,Maryam Mirahmad,Aida Iraji,Ahmad Shahir Sadr,Navid Dastyafteh,Pooria Asili,Gholami,Shahrzad Javanshir,Maryam Lotfi,Somayeh Mojtabavi,Mohammad Ali Faramarzi,Mehdi Asadi,Ensieh Nasli-Esfahani,Mahdie Palimi,Bagher Larijani,Mohammad Hadi Meshkatalsadat,Mohammad Mahdavi,Mahdi Gholami
DOI: https://doi.org/10.1016/j.ejmech.2024.116332
IF: 7.088
2024-03-17
European Journal of Medicinal Chemistry
Abstract:The inhibition of the α-glucosidase enzyme is crucial for targeting type 2 diabetes mellitus (DM). This study introduces a series of synthetic analogs based on thiomethylacetamide-quinoline derivatives linked to diphenyl-imidazole as highly potential α-glucosidase inhibitors. Twenty derivatives were synthesized and screened in vitro against α-glucosidase, revealing IC 50 values ranging from 0.18 ± 0.00 to 2.10 ± 0.07 μM, in comparison to the positive control, acarbose. Among these derivatives, compound 10c (IC 50 = 0.180 μM) demonstrated the highest potency and revealed a competitive inhibitory mechanism in kinetic studies ( K i = 0.15 μM). Docking and molecular dynamic evaluations elucidated the binding mode of 10c with the active site residues of the α-glucosidase enzyme. Moreover, in vivo assessments on a rat model of DM affirmed the anti-diabetic efficacy of 10c , evidenced by reduced fasting and overall blood glucose levels. The histopathological evaluation enhanced pancreatic islet architecture and hepatocytes in liver sections. In conclusion, novel thiomethylacetamide-quinoline derivatives as potent α-glucosidase inhibitors were developed. Compound 10c emerged as a promising candidate for diabetes management, warranting further investigation for potential clinical applications and mechanistic insights.
chemistry, medicinal